Vaxxinity VAXX Stock
Vaxxinity Price Chart
Vaxxinity VAXX Financial and Trading Overview
| Vaxxinity stock price | 0.25 USD |
| Previous Close | 2.03 USD |
| Open | 2.03 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 900 |
| Day's Range | 1.99 - 2.23 USD |
| 52 Week Range | 1.24 - 4.47 USD |
| Volume | 133.06K USD |
| Avg. Volume | 127.18K USD |
| Market Cap | 260.67M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.45 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.5 USD |
VAXX Valuation Measures
| Enterprise Value | 203.04M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.9855072 |
| PEG Ratio (5 yr expected) | 0.06 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 5.628415 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -2.719 |
Trading Information
Vaxxinity Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | -0.96% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 4.47 USD |
| 52 Week Low | 1.24 USD |
| 50-Day Moving Average | 2.04 USD |
| 200-Day Moving Average | 2.1 USD |
VAXX Share Statistics
| Avg. Volume (3 month) | 127.18K USD |
| Avg. Daily Volume (10-Days) | 104.87K USD |
| Shares Outstanding | 112.67M |
| Float | 38.34M |
| Short Ratio | 20.44 |
| % Held by Insiders | 55.92% |
| % Held by Institutions | 19.86% |
| Shares Short | 2.44M |
| Short % of Float | 5.72% |
| Short % of Shares Outstanding | 1.92% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -41.096% |
| Return on Equity (ttm) | -94.94% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -74686000 USD |
| Net Income Avi to Common (ttm) | -75380000 USD |
| Diluted EPS (ttm) | -0.61 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 67.82M USD |
| Total Cash Per Share (mrq) | 0.54 USD |
| Total Debt (mrq) | 13.99M USD |
| Total Debt/Equity (mrq) | 30.32 USD |
| Current Ratio (mrq) | 2.775 |
| Book Value Per Share (mrq) | 0.366 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -56465000 USD |
| Levered Free Cash Flow (ttm) | -38197000 USD |
Profile of Vaxxinity
| Country | United States |
| State | FL |
| City | Merritt Island |
| Address | 505 Odyssey Way |
| ZIP | 32953 |
| Phone | 254 244 5739 |
| Website | https://www.vaxxinity.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 87 |
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and VXX-301, an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; VXX-401 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Merritt Island, Florida.
Q&A For Vaxxinity Stock
What is a current VAXX stock price?
Vaxxinity VAXX stock price today per share is 0.25 USD.
How to purchase Vaxxinity stock?
You can buy VAXX shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Vaxxinity?
The stock symbol or ticker of Vaxxinity is VAXX.
Which industry does the Vaxxinity company belong to?
The Vaxxinity industry is Biotechnology.
How many shares does Vaxxinity have in circulation?
The max supply of Vaxxinity shares is 242.35M.
What is Vaxxinity Price to Earnings Ratio (PE Ratio)?
Vaxxinity PE Ratio is now.
What was Vaxxinity earnings per share over the trailing 12 months (TTM)?
Vaxxinity EPS is -0.45 USD over the trailing 12 months.
Which sector does the Vaxxinity company belong to?
The Vaxxinity sector is Healthcare.
Vaxxinity VAXX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
- {{ link.label }} {{link}}